Beactica and KU Leuven secure EUR 2.5 million from the European Innovation Council to advance orphan drug BEA-17 to clinical readiness
PR Newswire —
UPPSALA, Sweden, Feb. 17, 2026 /PRNewswire/ -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced that it, together with leading glioblastoma researchers at KU Leuven, has been awarded a EUR 2.5 million grant by the European Innovation Council (EIC) to advance...